Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: A retrospective cohort study
BMC Infectious Diseases Feb 02, 2018
Oh DH, et al. - Researchers performed a comparison of the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for methicillin-susceptible S. aureus (MSSA) bacteremia. In a group treated with glycopeptides, all-cause 28-day mortality rate was higher than in a group treated with nafcillin among patients with MSSA bacteremia. Therefore, they recommended considering the use of nafcillin as a definitive therapy for MSSA bacteremia.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries